Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase l Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Niraparib in Patients With Metastatic or Recurrent Solid Tumors

NCT06161493 is registered in ClinicalTrials.gov with Haider Mahdi as lead sponsor.

NCT NCT06161493
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06161493 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase l Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Niraparib in Patients With Metastatic or Recurrent Solid Tumors
Lead sponsor
Haider Mahdi
Phase
Phase 1
Overall status
Withdrawn
Start date
January 23, 2024
Completion date
December 31, 2029
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, recurrent solid tumors